{"prompt": "['GB001, Inc.', 'GB001', 'Protocol GB001-2101', 'Version 5.0, 16 Apr 2020', '7.3.', 'Lost to Follow-up', 'A subject will be considered lost to follow-up if he or she repeatedly fails to return for scheduled', 'visits and is unable to be contacted by the study site.', 'The following actions must be taken if a subject fails to return to the clinic for a required study', 'visit:', 'The site must attempt to contact the subject and reschedule the missed visit as soon as', 'possible and counsel the subject on the importance of maintaining the assigned visit', 'schedule and ascertain whether the subject wishes to and/or should continue in the', 'study.', 'Before a subject is deemed lost to follow up, the investigator or designee must make', 'every effort to regain contact with the subject (where possible, 3 telephone calls and,', \"if necessary, a certified letter to the subject's last known mailing address or local\", \"equivalent methods). These contact attempts should be documented in the subject's\", 'medical record.', 'The Sponsor may also attempt to ascertain vital status on subjects deemed lost to', 'follow up.', 'Should the subject continue to be unreachable, he/she will be considered to have', \"withdrawn from the study. The subject's data and biosamples may still be assayed, in\", 'accordance with his/her original informed consent.', '8.', 'STUDY ASSESSMENTS AND PROCEDURES', 'Study procedures and their timing are summarized in the SoA. Protocol waivers', 'or exemptions are not allowed.', 'Safety concerns should be discussed with the Sponsor immediately upon occurrence', 'or awareness to determine if the subject should continue or discontinue IP.', 'Adherence to the study design requirements, including those specified in the SoA,', 'is essential and required for study conduct.', 'All screening and randomization evaluations must be completed and reviewed to confirm that', 'potential subjects meet all eligibility criteria. The Investigator will maintain a log to record', 'details of all subjects screened to either confirm eligibility or record reasons for screening', 'or Run-in failures, as applicable. The suggested order of study procedures should be as follows.', '(Note: this list is not all inclusive. Review the SoA and the Study Reference Manual for', 'additional guidance.)', '35', 'CONFIDENTIAL']['GB001, Inc.', 'GB001', 'Protocol GB001-2101', 'Version 5.0, 16 Apr 2020', 'Screening Visit (Visit 1):', '(The list may not be all inclusive. Review the SoA and the Study Reference Manual for', 'additional guidance)', 'Informed consent', 'Demography', 'Administer SNOT-22', 'Medical/surgical history', 'Concomitant medication review including confirmation of INCS use for more than', '8 weeks prior to screening', 'Vital signs', 'Physical exam including visual exam of nose for polyps', '12-lead electrocardiogram', 'Review of inclusion/exclusion criteria', 'Collect urine and blood samples', 'Record adverse events, if any', 'Dispense Diary and train subject in its use including responding to the morning and', 'evening CRS symptom questions and daily MFNS use', 'Ensure subject has MFNS (or equivalent for non-US sites) for use as required', 'background therapy throughout the study.', 'Perform nasal endoscopy (subset of subjects). Endoscopy (including use of', 'decongestants and/or anesthetics before the procedure) will be performed after all', 'other efficacy assessments have been completed at each visit; video sequences will be', \"downloaded by the investigator to the blinded central reader's secure Internet site. For\", 'eligibility in the CRSwNP stratum, blinded central reading of the Visit 1 endoscopy', 'will be used.', 'Remind patient to bring diary materials to the next visit', 'Complete eCRF', 'Note: During the Run-in period, the site should review the central endoscopy overread report', 'and the laboratory results. If the overread or laboratory results indicate that the subject is not', 'eligible for randomization, the subject should be contacted to return all study provided materials', 'to the site.', '36', 'CONFIDENTIAL']['GB001, Inc.', 'GB001', 'Protocol GB001-2101', 'Version 5.0, 16 Apr 2020', 'Randomization Visit (Visit 2):', '(The list may not be all inclusive. Review the SoA and the Study Reference Manual for', 'additional guidance)', 'Review Diary to assess eligibility and remind subject to bring the materials to the', 'next visit', 'Review randomization eligibility criteria including results from blinded central reader', 'of Visit 1 nasal endoscopy to confirm entry criteria', 'Have subject complete questionnaires including SNOT-22', 'Concomitant medication and adverse event review', 'Vital signs', 'Reconfirm eligibility based on review of Inclusion/Exclusion Criteria (Section 5.3)', 'Collect lab samples', 'Perform CT scan. If a qualifiable CT scan has been performed within 30 days on the', 'qualified equipment consistent with the study imaging protocol and allowing', 'appropriate interpretation/assessment and the image sequences are available for', 'upload to the imaging core laboratory, then a CT scan on Visit 2 is not required. If a', 'historic CT scan is to be used this CT scan must be uploaded to the Imaging Core', 'Laboratory at a minimum of 14 days prior to the randomization visit to ensure image', 'quality and appropriate quantification.', 'Perform nasal endoscopy (only on subjects categorized as CRSwNP)', 'Perform nitric oxide measurements on all subjects.', 'Dispense IP', 'Complete eCRF', '8.1.', 'Efficacy Assessments', '8.1.1.', 'SNOT-22', 'The SNOT-22 (Section 10.9) is a validated questionnaire to assess the impact of chronic', 'rhinosinusitis on quality of life and utilizes a 2-week recall period. It is a 22-item outcome', 'measure on a 5-point category scale applicable to sinonasal conditions and surgical treatments.', 'The total scores range from 0 to 110 with higher total scores implying greater impact of CRS', 'on quality of life. A Minimal Clinically Important Difference (MCID) is available: 8.90', '(Hopkins, 2009).', '37', 'CONFIDENTIAL']\n\n###\n\n", "completion": "END"}